Current Problems in Cancer
Volume 31, Issue 6 , Pages 372-424 , November 2007

Leptomeningeal Metastasis

  • William P. O’Meara, MD, MPH

      Affiliations

    • Faculty Member, Department Radiation Oncology, National Naval Medical Center, Bethesda, Maryland
    • ,
  • Sunita A. Borkar

      Affiliations

    • Resident, Department of Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Hilda E. Stambuk

      Affiliations

    • Associate Attending Neuroradiologist, Department of Radiology, Division of Neuroradiology, Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Stella C. Lymberis

      Affiliations

    • Attending Assistant, Department of Radiation Oncolgy, Memorial Sloan-Kettering Cancer Center, New York, New York

References 

  1. Posner JB. Neurologic Complications of Cancer. Philadelphia, PA: F.A. Davis Company; 1995;
  2. Aisner J, Aisner SC, Ostrow S, Govindan S, Mummert K, Wiernik P. Meningeal carcinomatosis from small cell carcinoma of the lung (Consequence of improved survival). Acta Cytol. 1979;23(4):292–299
  3. Aroney RS, Dalley DN, Chan WK, Bell DR, Levi JA. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med. 1981;71(1):26–32
  4. Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer. 1995;76(2):232–236
  5. Gasecki AP, Bashir RM, Foley J. Leptomeningeal carcinomatosis: a report of 3 cases and review of the literature. Eur Neurol. 1992;32(2):74–78
  6. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin North Am. 1996;7(3):337–344
  7. Nugent JL, Bunn PA, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer. 1979;44(5):1885–1893
  8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106–130
  9. Kosmas C, Malamos NA, Tsavaris NB, et al. Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer. Oncology. 2002;63(1):6–15
  10. Kosmas C, Malamos NA, Tsavaris NB, et al. Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. J Neurooncol. 2002;56(3):265–273
  11. Rosen ST, Aisner J, Makuch RW, et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore). 1982;61(1):45–53
  12. Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer (Prognostic factors and influence of treatment). Cancer. 1991;67(6):1685–1695
  13. Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. Cancer. 1978;42(1):283–286
  14. Chamberlain MC. Neoplastic meningitis. Neurologist. 2006;12(4):179–187
  15. Chamberlain MC. Carcinomatous meningitis. Arch Neurol. 1997;54(1):16–17
  16. Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol. 1996;7(8):773–786
  17. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25(2):103–119
  18. Chamberlain MC, Nolan C, Abrey LE. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol. 2005;75(1):71–83
  19. DeAngelis LM, Boutros D. Leptomeningeal metastasis. Cancer Invest. 2005;23(2):145–154
  20. Groves MD. The pathogenesis of neoplastic meningitis. Curr Oncol Rep. 2003;5(1):15–23
  21. Seute T, Leffers P, ten Velde GP, Twijnstra A. Leptomeningeal metastases from small cell lung carcinoma. Cancer. 2005;104(8):1700–1705
  22. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin. 2003;21(1):25–66
  23. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–592
  24. Balm M, Hammack J. Leptomeningeal carcinomatosis (Presenting features and prognostic factors). Arch Neurol. 1996;53(7):626–632
  25. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49(4):759–772
  26. Fuchs IB, Loebbecke M, Buhler H, et al. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol. 2002;20(19):4130–4133
  27. Swirsky DM, Li YS, Matthews JG, Flemans RJ, Rees JK, Hayhoe FG. 8;21 translocation in acute granulocytic leukaemia: cytological, cytochemical and clinical features. Br J Haematol. 1984;56(2):199–213
  28. Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood. 1985;65(5):1071–1078
  29. Glass JP, Van Tassel P, Keating MJ, Cork A, Trujillo J, Holmes R. Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16. Neurology. 1987;37(4):639–644
  30. Hagemeijer A, Hahlen K, Sizoo W, Abels J. Translocation (9;11)(p21;q23) in three cases of acute monoblastic leukemia. Cancer Genet Cytogenet. 1982;5(2):95–105
  31. Wong ET, O’Brien S. Leptomeningeal disease in pre-leukemic syndrome: cytogenetic abnormality versus cellular morphology. Oncol Rep. 1998;5(2):493–495
  32. Barshes N, Demopoulos A, Engelhard HH. Anatomy and physiology of the leptomeninges and CSF space. Cancer Treat Res. 2005;125:1–16
  33. Esiri MM, Gay D. Immunological and neuropathological significance of the Virchow-Robin space. J Neurol Sci. 1990;100(1-2):3–8
  34. Sanan A, van Loveren HR. The arachnoid and the myth of Arachne. Neurosurgery. 1999;45(1):152–155
  35. Moore KL, Dalley AF. Clinically Oriented Anatomy. (4th ed). Philadelphia, PA: Lippincott Williams & Wilkins; 1999;
  36. Garton HJ, Piatt JH. Hydrocephalus. Pediatr Clin North Am. 2004;51(2):305–325
  37. Wolpow ER, Schaumburg HH. Structure of the human arachnoid granulation. J Neurosurg. 1972;37(6):724–727
  38. Milhorat TH. The third circulation revisited. J Neurosurg. 1975;42(6):628–645
  39. Yasargil MG, Kasdaglis K, Jain KK, Weber HP. Anatomical observations of the subarachnoid cisterns of the brain during surgery. J Neurosurg. 1976;44(3):298–302
  40. Rogers LR, Duchesneau PM, Nunez C, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology. 1992;42(6):1239–1241
  41. Kokkoris CP. Leptomeningeal carcinomatosis (How does cancer reach the pia-arachnoid?). Cancer. 1983;51(1):154–160
  42. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer (A clinical and pathologic study). Arch Neurol. 1974;30(2):122–137
  43. Price RA, Johnson WW. The central nervous system in childhood leukemia (I. The arachnoid). Cancer. 1973;31(3):520–533
  44. Hayat G, Ehsan T, Selhorst JB, Manepali A. Magnetic resonance evidence of perineural metastasis. J Neuroimaging. 1995;5(2):122–125
  45. Redman BG, Tapazoglou E, Al-Sarraf M. Meningeal carcinomatosis in head and neck cancer (Report of six cases and review of the literature). Cancer. 1986;58(12):2656–2661
  46. Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication. J Neurooncol. 1997;32(3):215–223
  47. van der Ree TC, Dippel DW, Avezaat CJ, Sillevis Smitt PA, Vecht CJ, van den Bent MJ. Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry. 1999;66(2):225–227
  48. Siomin VE, Vogelbaum MA, Kanner AA, Lee SY, Suh JH, Barnett GH. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol. 2004;67(1-2):115–121
  49. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med. 2003;3(7):643–651
  50. Nathoo N, Chahlavi A, Barnett GH, Toms SA. Pathobiology of brain metastases. J Clin Pathol. 2005;58(3):237–242
  51. Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol. 2006;33(3):312–323
  52. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660–668
  53. Houck WA, Olson KB, Horton J. Clinical features of tumor metastasis to the pituitary. Cancer. 1970;26(3):656–659
  54. Yap HY, Tashima CK, Blumenschein GR, Eckles N. Diabetes insipidus and breast cancer. Arch Intern Med. 1979;139(9):1009–1011
  55. Crawford NP, Hunter KW. New perspectives on hereditary influences in metastatic progression. Trends Genet. 2006;22(10):555–561
  56. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518–524
  57. Minn AJ, Kang Y, Serganova I, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005;115(1):44–55
  58. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904
  59. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990;9(3):225–229
  60. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20–27
  61. Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM. Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Mod Pathol. 2006;19(12):1521–1527
  62. X Practice Guidelines in Central Nervous System Cancers. 2006;Available from: http://www.nccn.org. Accessed December 12, 2006
  63. Hansen K, Gjerris F, Sorensen PS. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir (Wien). 1987;86(3-4):93–97
  64. Demopoulos A, Posner JB. Pathophysiology and clinical features of leptomeingeal metastases (carcinomatous meningitis). In: UpToDate. 2006;Waltham, MA
  65. Broderick JP, Cascino TL. Nonconvulsive status epilepticus in a patient with leptomeningeal cancer. Mayo Clin Proc. 1987;62(9):835–837
  66. Straathof CS, de Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol. 1999;246(9):810–814
  67. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology. 1990;40(3 Pt 1):435–438
  68. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51–57
  69. Jaeckle KA. Assessment of tumor markers in cerebrospinal fluid. Clin Lab Med. 1985;5(2):303–315
  70. Collie DA, Brush JP, Lammie GA, et al. Imaging features of leptomeningeal metastases. Clin Radiol. 1999;54(11):765–771
  71. Rodesch G, Van Bogaert P, Mavroudakis N, et al. Neuroradiologic findings in leptomeningeal carcinomatosis: the value interest of gadolinium-enhanced MRI. Neuroradiology. 1990;32(1):26–32
  72. Fukui MB, Meltzer CC, Kanal E, Smirniotopoulos JG. MR imaging of the meninges (Part II. Neoplastic disease). Radiology. 1996;201(3):605–612
  73. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369–1375
  74. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82(4):733–739
  75. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neurooncol. 2001;3(1):42–45
  76. Adachi N. Beta-2-microglobulin levels in the cerebrospinal fluid: their value as a disease marker (A review of the recent literature). Eur Neurol. 1991;31(4):181–185
  77. Ohta H, Koyama R, Nagai T, Hirayama Y, Saito S, Yonesaka A. Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation. Int J Clin Oncol. 2001;6(3):157–162
  78. Machado AB, Machado AA, Barbuto JA, de Oliveira RM. Central nervous system metastases from breast carcinoma (A clinical and laboratorial study in 47 patients). Ar Qneuropsiquiatr. 1998;56(2):188–192
  79. Mencel PJ, DeAngelis LM, Motzer RJ. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer. 1994;73(7):1892–1894
  80. Klee GG, Tallman RD, Goellner JR, Yanagihara T. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc. 1986;61(1):9–13
  81. Shuttleworth E, Allen N. CSF beta-glucuronidase assay in the diagnosis of neoplastic meningitis. Arch Neurol. 1980;37(11):684–687
  82. Twijnstra A, Ongerboer de Visser BW, van Zanten AP. Diagnosis of leptomeningeal metastasis. Clin Neurol Neurosurg. 1987;89(2):79–85
  83. Fleisher M, Wasserstrom WR, Schold SC, Schwartz MK, Posner JB. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer. 1981;47(11):2654–2659
  84. DeAngelis LM, Posner JB. Telomerase activity in brain and leptomeningeal metastases. J Neurol Sci. 1998;161(2):114–115
  85. Kleinschmidt-DeMasters BK, Evans LC, Bitter MA, Shroyer AL, Shroyer KR. Part II (Telomerase expression in cerebrospinal fluid specimens as an adjunct to cytologic diagnosis). J Neurol Sci. 1998;161(2):124–134
  86. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer. 2004;91(2):219–224
  87. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology. 2000;54(8):1670–1676
  88. Twijnstra A, Ongerboer de Visser BW, van Zanten AP, Hart AA, Nooyen WJ. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol. 1989;7(1):57–63
  89. Cibas ES, Malkin MG, Posner JB, Melamed MR. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid. Am J Clin Pathol. 1987;88(5):570–577
  90. Thomas JE, Falls E, Velasco ME, Zaher A. Diagnostic value of immunocytochemistry in leptomeningeal tumor dissemination. Arch Pathol Lab Med. 2000;124(5):759–761
  91. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002;58(3):390–396
  92. Rhodes CH, Glantz MJ, Glantz L, et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer. 1996;77(3):543–548
  93. Storch-Hagenlocher B, Haas J, Vogt-Schaden ME, et al. Molecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitis. Ann Neurol. 2000;47(2):211–217
  94. van Oostenbrugge RJ, Hopman AH, Ramaekers FC, Twijnstra A. In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol. 1998;38(2-3):127–133
  95. van Oostenbrugge RJ, Hopman AH, Arends JW, Ramaekers FC, Twijnstra A. Treatment of leptomeningeal metastases evaluated by interphase cytogenetics. J Clin Oncol. 2000;18(10):2053–2058
  96. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma. In: 1948;p. 634–656
  97. Demopoulos A, Posner JB. Treatment of leptomeningeal metastases (carcinomatous meningitis). In: UpToDate. 2006;Waltham, MA
  98. Greenfield JP, Bilsky MH. Neurosurgical interventions for leptomeningeal tumor. Cancer Treat Res. 2005;125:107–119
  99. Ommaya AK. Subcutaneous reservoir and pump for sterile access to ventricular cerebrospinal fluid. Lancet. 1963;282(7315):983–984
  100. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293(4):161–166
  101. Larson SM, Schall GL, Di Chiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med. 1971;12(8):555–557
  102. Galicich JH, Guido LJ. Ommaya device in carcinomatous and leukemic meningitis: surgical experience in 45 cases. Surg Clin North Am. 1974;54(4):915–922
  103. Lishner M, Perrin RG, Feld R, et al. Complications associated with Ommaya reservoirs in patients with cancer (The Princess Margaret Hospital experience and a review of the literature). Arch Intern Med. 1990;150(1):173–176
  104. Obbens EA, Leavens ME, Beal JW, Lee YY. Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology. 1985;35(9):1274–1278
  105. Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery. 2000;47(1):49–54
  106. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87(5):694–699
  107. Lemann W, Wiley RG, Posner JB. Leukoencephalopathy complicating intraventricular catheters: clinical, radiographic and pathologic study of 10 cases. J Neurooncol. 1988;6(1):67–74
  108. Shapiro WR, Chernik NL, Posner JB. Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch Neurol. 1973;28(2):96–102
  109. Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis (An evaluation using 111indium-DTPA ventriculography). Am J Med. 1982;73(5):641–647
  110. Chamberlain MC. Pediatric leptomeningeal metastasis: 111In-DTPA cerebrospinal fluid flow studies. J Child Neurol. 1994;9(2):150–154
  111. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111indium-DTPA CSF flow studies. Neurology. 1991;41(11):1765–1769
  112. Chiro GD, Hammock MK, Bleyer WA. Spinal descent of cerebrospinal fluid in man. Neurology. 1976;26(1):1–8
  113. Haaxma-Reiche H, Piers A, Beekhuis H. Normal cerebrospinal fluid dynamics (A study with intraventricular injection of 111In-DTPA in leukemia and lymphoma without meningeal involvement). Arch Neurol. 1989;46(9):997–999
  114. Larson SM, Johnston GS, Ommaya AK, Jones AE, Di Chiro G. The radionuclide ventriculogram. JAMA. 1973;224(6):853–857
  115. Lyons MK, Meyer FB. Cerebrospinal fluid physiology and the management of increased intracranial pressure. Mayo Clin Proc. 1990;65(5):684–707
  116. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases. J Neurooncol. 1995;23(3):233–238
  117. Chamberlain MC. Spinal 111Indium-DTPA CSF flow studies in leptomeningeal metastasis. J Neurooncol. 1995;25(2):135–141
  118. Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol. 1998;38(2-3):135–140
  119. Mason WP, Yeh SD, DeAngelis LM. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology. 1998;50(2):438–444
  120. Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology. 1996;46(6):1674–1677
  121. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer. 1995;75(12):2919–2931
  122. Mehta M, Bradley K. Radiation therapy for leptomeningeal cancer. Cancer Treat Res. 2005;125:147–158
  123. Gray JR, Wallner KE. Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia. Int J Radiat Oncol Biol Phys. 1990;19(2):439–444
  124. Hermann B, Hultenschmidt B, Sautter-Bihl ML. Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis. Strahlenther Onkol. 2001;177(4):195–199
  125. Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol. 2005;75(1):85–99
  126. Bezek S, Trnovec T, Scasnar V, et al. Irradiation of the head by 60Co opens the blood-brain barrier for drugs in rats. Experientia. 1990;46(10):1017–1020
  127. d’Avella D, Cicciarello R, Angileri FF, Lucerna S, La Torre D, Tomasello F. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl. 1998;71:282–284
  128. Delattre JY, Shapiro WR, Posner JB. Acute effects of low-dose cranial irradiation on regional capillary permeability in experimental brain tumors. J Neurol Sci. 1989;90(2):147–153
  129. Krueck WG, Schmiedl UP, Maravilla KR, Spence AM, Starr FL, Kenney J. MR assessment of radiation-induced blood-brain barrier permeability changes in rat glioma model. AJNR Am J Neuroradiol. 1994;15(4):625–632
  130. Rubin P, Gash DM, Hansen JT, Nelson DF, Williams JP. Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiother Oncol. 1994;31(1):51–60
  131. Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys. 1995;31(5):1093–1112
  132. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813–820
  133. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202–4208
  134. Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep. 2003;5(1):24–28
  135. Bauman G, Wong E, Trenka K, Scott D. A simple technique for craniospinal radiotherapy in the supine position. Radiother Oncol. 2006;80(3):394
  136. Malik M, Prabhakar R, Sharma DN, Rath GK. Retinoblastoma with cerebrospinal fluid metastasis treated with orbital and craniospinal irradiation using IMRT. Technol Cancer Res Treat. 2006;5(5):497–501
  137. Wilkinson JM, Lewis J, Lawrence GP, Lucraft HH, Murphy E. Craniospinal irradiation using a forward planned segmented field technique. Br J Radiol. 2007;80(951):209–215
  138. St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys. 2004;58(3):727–734
  139. Yuh GE, Loredo LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J. 2004;10(6):386–390
  140. D’Angio GJ, French LA, Stadlan EM, Kieffer SA. Intrathecal radioisotopes for the treatment of brain tumors. Clin Neurosurg. 1968;15:288–300
  141. Doge H, Hliscs R. Intrathecal therapy with 198Au-colloid for meningosis prophylaxis. Eur J Nucl Med. 1984;9(3):125–128
  142. Metz O, Stoll W, Plenert W. Meningosis prophylaxis with intrathecal 198Au-colloid and methotrexate in childhood acute lymphocytic leukemia. Cancer. 1982;49(2):224–228
  143. Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies (Results of responses and long term follow-up in 40 patients). J Neurooncol. 1998;38(2-3):225–232
  144. Coakham HB, Richardson RB, Davies AG, Bourne SP, Eckert H, Kemshead JT. Neoplastic meningitis from a pineal tumour treated by antibody-guided irradiation via the intrathecal route. Br J Neurosurg. 1988;2(2):199–209
  145. Coakham HB, Richardson RB, Davies AG, et al. Antibody-guided radiation therapy via the CSF for malignant meningitis. Lancet. 1986;2(8511):860–861
  146. Moseley RP, Davies AG, Richardson RB, et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer. 1990;62(4):637–642
  147. Hafeli UO, Sweeney SM, Beresford BA, Sim EH, Macklis RM. Magnetically directed poly(lactic acid) 90Y-microspheres: novel agents for targeted intracavitary radiotherapy. J Biomed Mater Res. 1994;28(8):901–908
  148. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol. 1998;16(4):1561–1567
  149. Bleyer WA, Coccia PF, Sather HN, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol. 1983;1(5):317–325
  150. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet. 2005;44(1):1–31
  151. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394–3402
  152. Jaeckle KA, Batchelor T, O’Day SJ, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002;57(3):231–239
  153. Jaeckle KA, Phuphanich S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001;84(2):157–163
  154. Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101) (A phase I study). Arch Neurol. 1993;50(3):261–264
  155. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003;97(12):3053–3060
  156. Trump DL, Grossman SA, Thompson G, Murray K, Wharam M. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep. 1982;66(7):1549–1551
  157. Boogerd W, van den Bent MJ, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004;40(18):2726–2733
  158. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994;44(8):1463–1469
  159. Herrlinger U, Forschler H, Kuker W, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci. 2004;223(2):167–178
  160. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol. 1994;51(5):457–461
  161. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?. J Neurooncol. 1998;38(2-3):151–157
  162. Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985;12(2):131–148
  163. Frank JA, Girton M, Dwyer AJ, Wright DC, Cohen PJ, Doppman JL. Meningeal carcinomatosis in the VX2 rabbit tumor model: detection with Gd-DTPA-enhanced MR imaging. Radiology. 1988;167(3):825–829
  164. Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep. 1977;61(4):633–641
  165. Grossman SA, Reinhard CS, Loats HL. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J Neurooncol. 1989;7(4):319–328
  166. Morra E, Lazzarino M, Brusamolino E, et al. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia (Clinical results in 46 patients). Cancer. 1993;72(2):439–445
  167. Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol. 2000;46(1):19–26
  168. Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;55(1):117–119
  169. Baculi RH, Suki S, Nisbett J, Leeds N, Groves M. Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol. 2001;19(13):3297–3298
  170. Ohta M, Tokuda Y, Suzuki Y, et al. A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody. Jpn J Clin Oncol. 2001;31(11):553–556
  171. Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neurooncol. 2004;6(1):63–64
  172. Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol. 2003;65(2):167–172
  173. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg. 1995;83(6):1029–1037
  174. Siegal T. Toxicity of treatment for neoplastic meningitis. Curr Oncol Rep. 2003;5(1):41–49
  175. Geiser CF, Bishop Y, Jaffe N, Furman L, Traggis D, Frei E. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood. 1975;45(2):189–195
  176. Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med. 2001;345(6):425–432
  177. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82(9):1756–1763
  178. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12(3):627–642
  179. Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys. 1980;6(9):1215–1228
  180. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep. 1981;65(S1):89–98
  181. Bleyer WA, Nelson JA, Kamen BA. Accumulation of methotrexate in systemic tissues after intrathecal administration. J Pediatr Hematol Oncol. 1997;19(6):530–532
  182. Mehta BM, Glass JP, Shapiro WR. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Res. 1983;43(1):435–438
  183. Stapleton S, Blaney S. New agents for intrathecal administration. Cancer Invest. 2006;24(5):528–534
  184. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006;106(9):2021–2027
  185. Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005;23(7):1555–1563
  186. Blaney SM, Boyett J, Friedman H, et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005;23(3):525–531
  187. Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003;21(1):143–147
  188. Kochi M, Kuratsu J, Mihara Y, et al. Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride. Neurosurgery. 1993;33(5):817–823
  189. Ushio Y, Kochi M. Intrathecal perfusion chemotherapy with ACNU against subarachnoid dissemination of glioma in children. Int J Pediatr Hematol Oncol. 1998;5(1):55–56
  190. Ushio Y, Kochi M, Kitamura I, Kuratsu JI. Ventriculolumber perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride for subarachnoid dissemination of gliomas. J Neurooncol. 1998;38(2-3):207–212
  191. Chen YM, Chen MC, Tsai CM, Perng RP. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis: a case report. Lung Cancer. 2003;40(1):99–101
  192. Sampson JH, Archer GE, Villavicencio AT, et al. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res. 1999;5(5):1183–1188
  193. Friedman HS, Archer GE, McLendon RE, et al. Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. Cancer Res. 1994;54(17):4710–4714
  194. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002;94(10):2675–2680
  195. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol. 1989;7(11):1701–1709
  196. Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother. 1993;13(1):49–54
  197. Herrlinger U, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. J Neurooncol. 1998;38(2-3):233–239
  198. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 2006;7(9):778–780
  199. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep. 2006;15(5):1373–1377
  200. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer. 2001;2(3):235
  201. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica. 2004;89(6):753–754
  202. Herrlinger U, Schmidberger H, Buchholz R, Wehrmann M, Vallera DA, Schabet M. Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin. J Neurooncol. 1998;40(1):1–9
  203. Bigner DD, Archer GE, McLendon RE, et al. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin Cancer Res. 1995;1(12):1545–1555
  204. Hall WA, Myklebust A, Godal A, Nesland JM, Fodstad O. In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery. 1994;34(4):649–655
  205. Cokgor I, Akabani G, Friedman HS, et al. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)(2): a case study. Cancer. 2001;91(9):1809–1813
  206. Bigner DD, Brown M, Coleman RE, et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F(ab′)2: a preliminary report. J Neurooncol. 1995;24(1):109–122
  207. Kramer K, Cheung NK, Humm JL, et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol. 2000;35(6):716–718
  208. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001;61(10):4048–4054
  209. Aiken RD. Neurologic complications of head and neck cancers. Semin Oncol. 2006;33(3):348–351
  210. Giglio P, Weinberg JS, Forman AD, Wolff R, Groves MD. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer. 2005;103(11):2355–2362
  211. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005;16(11):1772–1777
  212. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24(8):1281–1288
  213. Chamberlain MC. Leptomeningeal metastases: a review of evaluation and treatment. J Neurooncol. 1998;37(3):271–284

PII: S0147-0272(07)00047-5

doi: 10.1016/j.currproblcancer.2007.07.001

Current Problems in Cancer
Volume 31, Issue 6 , Pages 372-424 , November 2007

Article Tools

* Image Usage & Resolution